Skip to main content
Log in

Klassifikation, genetische Prädisposition und Risikofaktoren für die Entwicklung einer Kardiomyopathie

Classification, genetic predisposition and risk factors for the development of cardiomyopathies

  • Schwerpunkt: Herzerkrankungen
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Die Kardiomyopathien stellen eine breit gefächerte und klinisch wichtige Gruppe von Erkrankungen dar, deren wesentliches Merkmal eine krankhafte Veränderung des Herzmuskels selbst ist. Sie münden häufig in schwerer Herzinsuffizienz oder zeigen Arrhythmien bis zum plötzlichen Herztod. Die klinische und morphologische Diversität der unterschiedlichen Kardiomyopathien reflektiert möglicherweise das breite Spektrum verschiedenster zugrunde liegender molekularer Ursachen, eine große genetische Heterogenität oder das Vorhandensein von weiteren Faktoren, die den Krankheitsausbruch, den Verlauf und die Prognose beeinflussen. Der individiuelle Phänotyp eines Patienten kann unter Umständen als die Summe und Interaktion von zugrunde liegender Mutation mit anderen genetischen Faktoren plus bestimmten Umweltfaktoren sein. Große Fortschritte wurden in den letzten Jahren bezüglich des pathogenetischen Verständnisses von Kardiomyopathien vor allem durch molekulare Techniken erzielt. Trotzdem müssen die wissenschaftlichen Untersuchung bei Patienten mit Kardiomyopathien weiter voranschreiten, um eine Fortentwicklung unseres Verständnisses als unabdingbare Voraussetzung für möglicherweise ätiologisch orientierte Therapieformen zu ermöglichen.

Abstract

Cardiomyopathies are an important and diverse group of heart muscle diseases in which the heart muscle itself is structural or functional abnormal. This often results in severe heart failure accompanied by arrhythmias and/or sudden death. Clinical and morphological diversity of cardiomyopathies can reflect the broad spectrum of distinct underlying molecular causes or genetic heterogeneity. In addition, modifying genes, life style and additional factors were reported to influence onset of disease, disease progression and prognosis. The individual patient’s phenotype may reflect a summation and/or interaction of the underlying mutation with other genetic or environmental factors. During the last years major advances have been made in the understanding of the molecular and genetic basis of this type of disease. Nevertheless, much more progress in the identification of underlying mutations, susceptibility genes and modifier genes is important and indispensable for the development of new etiology orientated forms of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Alcalai R, Seidman JG, Seidmann CE (2008) Genetic basis of hypertrophic cardiomyopathy: From bench to clinics. J Cardiovasc Electrophysiol 19: 104–110

    PubMed  Google Scholar 

  2. Angelow A, Schidt M, Hoffmann W (2007) Towards risk factor assessment in inflammatory dilated cardiomyopathy: the SFB/TR 19 study. Eur J Cardiovasc Prev Rehabil 14: 686–693

    Article  PubMed  Google Scholar 

  3. Arad M, Seidman JG, Seidman CE (2002) Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet 11: 2499–2506

    Article  PubMed  CAS  Google Scholar 

  4. Arbustini E, Morbini P, Pilotto A et al. (2001) Familial dilated cardiomyopathy: from clinical presentation to molecular genetics. Am J Hum Genet 69: 249–260

    Article  Google Scholar 

  5. Ashrafian H, Watkins H (2007) Reviews of translational medicine and genomics in cardiovascular disease: new disease taxonomy and therapeutic implications cardiomyopathies: therapeutics based on molecular phenotype. J Am Coll Cardiol 49: 1251–1264

    Article  PubMed  CAS  Google Scholar 

  6. Basso C, Thiene G, Corrado D et al. (1996) Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy or myocarditis? Circulation 94: 983–991

    PubMed  CAS  Google Scholar 

  7. Bien S, Riad A, Ritter CA et al. (2007) The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res 67: 10428–10435

    Article  PubMed  CAS  Google Scholar 

  8. Burkett EL, Hershberger RE (2005) Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 45: 969–981

    Article  PubMed  CAS  Google Scholar 

  9. Corrado D, Fontaine G, Marcus FI et al. (2000) Arrhythmogenic right ventricular dysplasia/cardiomyopathy; need for an international registry. Study group on arrhythmogenic right ventricular dysplasia/cardiomyopathy of the working groups of myocardial and pericardial disease and arrhythmias of the European Society of Cardiology and of the scientific council of cardiomyopathies of the World Heart Federation. Circulation 101: E101–E106

    PubMed  CAS  Google Scholar 

  10. Coughlin SS, Tefft MC, Rice JC et al. (1996) Epidemiology of idiopathic dilated cardiomyopathy in the elderly: pooled results from two case-control studies. Am J Epidemiol 143: 881–888

    PubMed  CAS  Google Scholar 

  11. Deng S, Kulle B, Hosseini M et al. (2007) Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity. Eur J Heart Fail 9: 986–994

    Article  PubMed  CAS  Google Scholar 

  12. Elliott P, Andersson B, Arbustini E et al. (2008) Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. Eur Heart J 29: 207–276

    Google Scholar 

  13. Forleo C, Sorrentino S, Guida P et al. (2007) β1- und β2-adrenergic receptor polymorphisms affect susceptibility to idiopathic dilated cardiomyopathy. J Cardiovasc Med 8: 589–595

    Article  Google Scholar 

  14. Kühl U, Pauschinger M, Noutsias M et al. (2005) High prevalence of viral genomes and multiple viral infections in the myocardium of adults with „idiopathic“ left ventricular dysfunction. Circulation 111: 887–893

    Article  PubMed  Google Scholar 

  15. Kushwaha SS, Fallon JT, Fuster V (1997) Restrictive cardiomyopathy. N Engl J Med 336: 267–276

    Article  PubMed  CAS  Google Scholar 

  16. Maisch B, Richter A, Sandmöller A et al. BMBF-Heart Failure Network (2005) Inflammatory dilated cardiomyopathy (DCMI). Herz 30: 535–544

    Article  PubMed  Google Scholar 

  17. Markiewicz-Łoskot G, Moric-Janiszewska E, Łoskot M et al. (2006) Isolated ventricular non-compaction: clinical study and genetic review. Europace 8: 1064–1068

    Article  PubMed  Google Scholar 

  18. Maron BJ, Gardin JM, Flack JM et al. (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 91: 785–789

    Google Scholar 

  19. Maron BJ, Towbin JA, Thiene G et al. (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113: 1807–1816

    Article  PubMed  Google Scholar 

  20. Mason JW (2003) Myocarditis and dilated cardiomyopathy: An inflammatory link. Cardiovasc Res 60: 5–10

    Article  PubMed  CAS  Google Scholar 

  21. McKenna CJ, Codd MB, McCann HA, Sugrue DD (1997) Idiopathic dilated cardiomyopathy: familial prevalence and HLA distribution. Heart 77: 549–552

    PubMed  CAS  Google Scholar 

  22. Miura K, Nakagawa H, Toyoshima H et al. (2004) Environmental factors and risk of idiopathic dilated cardiomyopathy: a multi-hospital case-control study in Japan. Circ J 68: 1011–1017

    Article  PubMed  Google Scholar 

  23. Mogensen J, Kubo T, Duque M et al. (2003) Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest 111: 209–216

    PubMed  CAS  Google Scholar 

  24. Pankuweit S, Baandrup U, Moll R et al. (2003) Prevalence of Parvovirus B 19 genome in endomyocardial biopsy specimen. Hum Pathol 34: 80–86

    Article  Google Scholar 

  25. Poller W, Kühl U, Tschoepe C et al. (2005) Genome-environment interactions in the molecular pathogenesis of dilated cardiomyopathy. J Mol Med 83: 579–586

    Article  PubMed  CAS  Google Scholar 

  26. Portig I, Wilke A, Freyland M et al. (2006) Familial inflammatory dilated cardiomyopathy. Eur J Heart Fail 8: 816–825

    Article  PubMed  CAS  Google Scholar 

  27. Pruszczyk P, Kostera-Pruszczyk A, Shatunov A et al. (2007) Restrictive cardiomyopathy with atrioventricular conduction block resulting from a desmin mutation. Int J Cardiol 117: 244–253

    Article  PubMed  Google Scholar 

  28. WHO/ISFC Task Force (1980) Report of the WHO/ISFC Task Force on the definition and classification of cardiomyopathies. Br Heart J 44: 672–674

    Article  Google Scholar 

  29. Richard P, Charron P, Carrier L et al. (2003) Hypertrophic cardiomyopathy: Distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107: 2227–2232

    Article  PubMed  Google Scholar 

  30. Richardson P, McKenna W, Bristow M et al. (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93: 841–842

    PubMed  CAS  Google Scholar 

  31. Rodríguez-Pérez JM, Fragoso JM, Alvarez-León E et al. (2007) MHC class II genes in Mexican patients with idiopathic dilated cardiomyopathy. Exp Mol Pathol 82: 49–52

    Article  PubMed  CAS  Google Scholar 

  32. Shaw T, Elliot P, McKenna WJ (2002) Dilated cardiomyopathy: a genetical heterogeneous disease. Lancet 360: 654–655

    Article  PubMed  Google Scholar 

  33. Thiene G, Corrado D, Basso C (2004) Cardiomyopathies: is it time for a molecular classification? Eur Heart J 25: 1772–1775

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. Pankuweit.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pankuweit, S., Richter, A., Ruppert, V. et al. Klassifikation, genetische Prädisposition und Risikofaktoren für die Entwicklung einer Kardiomyopathie. Internist 49, 441–447 (2008). https://doi.org/10.1007/s00108-008-2050-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-008-2050-y

Schlüsselwörter

Keywords

Navigation